Is Ionis Pharmaceuticals, Inc. (IONS) a Buy, Sell, or Hold?
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$54.93 USD
-$1.82 (-3.21%)
- Volume
- 4.7M
- Average Volume
- 2.42M
- Market Capitalization
- $9.08B
- P/E Ratio
- -27.60
- Dividend Yield
- 0.00%
- Price Target
- $90.00
- Year High
- $86.74
- Year Low
- $40.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.10
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Brett Monia |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IONS |
| CUSIP | 462222100 |
| CIK | 0000874015 |
| Web | https://www.ionis.com |
| Phone | 760 931 9200 |
| Currency | USD |
| Employees | 1402 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 4.15 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.10 |
| Quick Ratio | 4.09 |
| Cash Ratio | 0.24 |
Sales & Book Value
| Annual Sales | $944M |
| Price / Sales | 8.58 |
| Cash Flow | -5.89 |
| Price / Cash Flow | -9.35 |
| Price / Book | 18.43 |
Price Target and Rating
| Average Stock Price Forecast | $90.00 |
| High Stock Price Forecast | $130.00 |
| Low Stock Price Forecast | $75.00 |
| Forecast Upside/Downside | -38.97% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 33 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.38 |
| Trailing P/E Ratio | -27.60 |
| PEG Ratio | 5.15 |
| P/E Growth | 5.15 |
| Net Income | $-381M |
| Net Margin | -30.87% |
| Pretax Margin | -30.74% |
| Return on Equity | -58.57% |
| Return on Assets | -9.47% |
Financials Score
| AltmanZ Score | 1.58 |
| Piotroski Score | 2.00 |
| Working Capital | 2.22B |
| Total Assets | 3.45B |
| Ebit | -248.37M |
| Market Cap | 9.08B |
| Total Liabilities | 2.96B |
Poll Results
About Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all fo ... rms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
2026-07-14 17:00:28
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw. com or 646-581-9980, ext. 7980.
2026-07-14 17:00:00
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
2026-07-14 12:17:00
SAN FRANCISCO, July 14, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders' rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial's data and design and, if not, whether the company may have violated the federal securities laws.
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
2026-07-14 11:06:11
IONS doses first patient in the phase I/II ASCEND study of ION337, marking a key step in developing a potential disease-modifying treatment for Dravet syndrome.
2026-07-14 10:20:00
Ionis Pharmaceuticals (NASDAQ: IONS) investors absorbed a >20% share decline after the Phase-3 CARDIO-TTRansform trial missed its primary endpoint. Levi & Korsinsky is investigating potential securities law violations.
2026-07-14 10:00:00
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranerse
2026-07-14 09:16:00
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer's disease. The data, presented at the Alzheimer's Association International Conference (AAIC) 2026, expand upon previously reported topline results and demonstrate a combination of meaningful clinical effi.
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
2026-07-13 12:25:30
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.
Frequently Asked Questions
-
What is the current Ionis Pharmaceuticals, Inc. (IONS) stock price?
-
Ionis Pharmaceuticals, Inc.(NASDAQ:IONS) stock price is $54.93 in the last trading session. During the trading session, IONS stock reached the peak price of $86.74 while $40.03 was the lowest point it dropped to. The percentage change in IONS stock occurred in the recent session was --3.21% while the dollar amount for the price change in IONS stock was -$-1.82.
-
IONS's industry and sector of operation?
-
The NASDAQ listed IONS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IONS?
-
Brian Birchler | Executive Vice President of Corporate & Development Operations
C. Frank Bennett | Executive Vice President & Chief Scientific Officer
Elizabeth L. Hougen | Executive Vice President of Finance & Chief Financial Officer
Eric E. Swayze | Executive Vice President of Research
Eugene Schneider | Executive Vice President, Chief Clinical Development & Operations Officer -
How many employees does IONS have?
-
Number of IONS employees currently stands at 1402. IONS operates from 2855 Gazelle Court, Carlsbad, CA 92010, US.
-
Link for IONS official website?
-
Official Website of IONS is: https://www.ionis.com
-
How do I contact IONS?
-
IONS could be contacted at phone #760 931 9200 and can also be accessed through its website. IONS operates from 2855 Gazelle Court, Carlsbad, CA 92010, US.
-
How many shares of IONS are traded daily?
-
The average number of IONS shares traded daily for last 3 months was 2.42M.
-
What is the market cap of IONS currently?
-
The market value of IONS currently stands at $9.08B with its latest stock price at $54.93